Skip main navigation

Coffee Consumption and Coronary Artery Calcium Score: Cross‐Sectional Results of ELSA‐Brasil (Brazilian Longitudinal Study of Adult Health)

Originally published of the American Heart Association. 2018;7:e007155



    Available evidence for the relationship between coffee intake and subclinical atherosclerosis is limited and inconsistent. This study aimed to evaluate the association between coffee consumption and coronary artery calcium (CAC) in ELSA‐Brasil (Brazilian Longitudinal Study of Adult Health).

    Methods and Results

    This cross‐sectional study is based on baseline data from participants of the ELSA‐Brasil cohort. Only participants living in São Paulo, Brazil, who underwent a CAC measurement (n=4426) were included. Coffee consumption was collected using a food frequency questionnaire. CAC was detected with computed tomography and expressed as Agatston units. CAC was further categorized as an Agatson score ≥100 (CAC ≥100). In multiple logistic regression analysis considering intake of coffee and smoking status interaction, significant inverse associations were observed between coffee consumption (>3 cups/d) and CAC≥100 (odds ratio [OR]: 0.85 [95% confidence interval, 0.58–1.24] for ≤1 cup/d; OR: 0.73 [95% confidence interval, 0.51–1.05] for 1–3 cups/d; OR: 0.33 [95% confidence interval, 0.17–0.65] for >3 cups/d). Moreover, there was a statistically significant interaction effect for coffee consumption and smoking status (P=0.028 for interaction). After stratification by smoking status, the analysis revealed a lower OR of coronary calcification in never smokers drinking >3 cups/d (OR: 0.37 [95% confidence interval, 0.15–0.91]), whereas among current and former smokers, the intake of coffee was not significantly associated with coronary calcification.


    Habitual consumption of >3 cups/d of coffee decreased odds of subclinical atherosclerosis among never smokers. The consumption of coffee could exert a potential beneficial effect against coronary calcification, particularly in nonsmokers.

    Clinical perspective

    What Is New?

    • We observed that the association between coffee consumption and coronary calcification was related to smoking status.

    • Drinking >3 cups/d of coffee was associated with lower odds of subclinical coronary atherosclerosis in never smokers.

    What Are the Clinical Implications?

    • Based on our results and prior studies, consumption of coffee could exert a potential beneficial effect against coronary calcification and cardiovascular disease risk, particularly in nonsmokers.

    • It is possible that deleterious effects of smoking overwhelm the benefits of coffee intake on early cardiovascular disease injury, so this impact of coffee may occur only in people who have never smoked.

    Cardiovascular diseases (CVD) are the leading global cause of death from noncommunicable diseases, accounting for 17.9 million deaths/y in 20151 and predicted to rise to >23.6 million by 2030.2 From 2005 to 2013, the number of disability‐adjusted life‐years increased for CVD.3 Reducing these numbers, with the consequent reduction in morbidity and mortality related to CVD, has been a main objective of public health policies worldwide.1

    Lifestyle and dietary factors, such as a lack of physical activity, excess body weight, smoking, excessive alcohol intake, and unhealthy diet, are implicated in the etiology of CVD.4, 5 Coffee is one of the most popular and widely consumed nonalcoholic beverages in the world, and its role in CVD is still being debated and remains controversial.5, 6, 7 In this context, some epidemiological studies suggested a positive association between coffee consumption and risk of CVD,8, 9 whereas others reported no association6, 10 or even an inverse association.11, 12, 13

    Coffee is a complex mixture of several compounds including caffeine, minerals, fiber, and other biologically active components, such as diterpene alcohols, cafestol and kahweol, and phenolic acids, that influence human homeostasis and metabolism, and they may have either harmful or beneficial cardiovascular effects.14

    The presence of coronary artery calcium (CAC) is a well‐known and independent marker of subclinical atherosclerosis and a good predictor of future risk of cardiovascular events and all‐cause mortality in individuals with no previous history of CVD.15, 16, 17 The CAC detected by cardiac computed tomography (CT) is an accurate noninvasive measurement for atherosclerosis in coronary arteries.18, 19 CAC provides information on underlying pathologic changes in coronary arteries, allowing for detailed assessment of the early stages of CVD.20

    Although the relationship between coffee consumption and metabolic risk factors for CVD has been a topic of frequent interest, few studies have determined whether coffee drinking influences subclinical atherosclerosis. In fact, at this moment, only 4 studies have investigated the relationship between coffee consumption and CAC, with limited and inconsistent results.21, 22, 23, 24 Further investigation is needed regarding this issue.

    We aimed to evaluate the association between habitual coffee consumption and subclinical atherosclerosis measured as CAC during the baseline examination of middle‐aged participants in ELSA‐Brasil (Brazilian Longitudinal Study of Adult Health).

    Material and Methods

    Study Design and Population

    Because of the sensitive nature of the data collected for this study, requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to Center for Clinical and Epidemiological Research, University Hospital, University of São Paulo at Av. Lineu Prestes no 2565, 3° andar, São Paulo, SP, Brazil, CEP 05508‐000.

    ELSA‐Brasil is a cohort study designed to identify risk factors for diabetes mellitus and CVD. Further details of the study, including design, eligibility criteria, sources and methods of recruitment, and measurements obtained, have been described elsewhere.25, 26 Briefly, the cohort comprises 15 105 civil servants, aged 35 to 74 years at baseline, who were sampled from universities located in 6 Brazilian cities (Belo Horizonte, Porto Alegre, Rio de Janeiro, Salvador, São Paulo, and Vitoria).

    Baseline assessment was conducted from August 2008 to December 2010 and consisted of ≈7‐hour evaluation, which included personal interviews conducted by trained personnel. These interviews focused on sociodemographic characteristics, health and medical history, occupational exposure, family history of disease, reproductive health, health care, psychosocial factors, body weight history and body image, food consumption, smoking, alcohol consumption, physical activity, medication use, cognitive function, mental health, and clinical and laboratory measurements. In addition, the participants at the ELSA‐Brasil site in São Paulo (n=5061) were invited to perform a CT examination to quantify CAC.

    For the current investigation, only participants of ELSA‐Brasil at the São Paulo Research Center who underwent CAC determination (n=4549) were included. In addition, in the present analysis, we excluded individuals with missing data at baseline for coffee intake (n=2) and self‐reported history of CVD, defined as prior myocardial infarction, angina, stroke, heart failure, or coronary revascularization (n=121). The final study sample comprised 4426 individuals who underwent CAC measurements and who did not fulfill exclusion criteria to participate in this subset of the study.

    The ELSA‐Brasil protocol was approved at all 6 centers by the institutional review boards addressing research in human participants. All participants signed a written informed consent form.

    Assessment of Coffee Consumption

    Dietary data were collected using a validated, semiquantitative, 114‐item food frequency questionnaire to provide information on typical eating habits of participants (ie, foods and drinks) in the 12 months before the baseline examination of ELSA‐Brasil. More details are available elsewhere.27 For the assessment of habitual coffee intake, specifically, participants were asked to provide both the typical frequency with which they consumed coffee (“More than 3 times per day,” “2–3 times per day,” “once a day,” “5–6 times per week,” “2–4 per week,” “once a week,” “1–3 times a month” and “never or almost never”) and the quantity of coffee consumed on each occasion in relation to a reference cup size of 50 mL, which is the household measure adopted in Brazil. Participants were further asked to specify the type of coffee normally consumed (filter, instant, espresso, moka pot), whether this coffee contained caffeine (caffeinated or decaffeinated), and whether additional items were typically added to the coffee (sugar, artificial sweetener, none). Daily coffee consumption (mL/d) was estimated and then classified into 4 categories (in cups/d): never/almost never or ≤1, 1 to 3, or >3 cups/d. The never/almost never category was used as the reference group.

    The Food Frequency Questionnaire ELSA‐Brasil used the Nutrition Data System for Research software (University of Minnesota), which is mainly based on data from the food composition table published by the US Department for Agriculture and the Tabela Brasileira de Composição de Alimentos ( to obtain the nutritional information of the 114 items listed in the food frequency questionnaire, such as dietary nutrients, total energy, and other food components.

    CAC Measurement

    The ELSA‐Brasil participants from the São Paulo site underwent noncontrast CT for CAC score evaluation.28, 29 The scans were performed using a 64‐detector CT scanner (Brilliance 64; Philips Healthcare). The field of view was set to include the entire heart, and the z‐axis direction included data from the bifurcation of the pulmonary arteries to the apex of the heart during an expiratory pause. The default settings included 120 kV, mA adjusted to body mass index, 1‐phase prospective acquisition at 70% (mid‐diastole) of the cardiac cycle and collimation of 2.5 mm, gantry rotation of 400 ms, and reconstruction with a standard filter. CT images were evaluated in blinded form by an experienced cardiologist using a semiautomatic software (Calcium Scoring; Philips Workstation). The measurement of the CAC score was calculated using a threshold of 130 Hounsfield units and expressed in Agatston units.30 CAC severity was further categorized with a cutoff at 100 points because it is a better marker of worse prognosis than CAC >0.31, 32, 33

    Covariate Assessment

    Each participant was interviewed at his or her workplace and visited the research center for clinical examinations according to standard protocols.34 Consequently, all covariates included in this analysis were self‐reported through standardized questionnaires or obtained through clinical procedures or laboratory examination measurements, performed by trained personnel under strict quality control at ELSA‐Brasil baseline assessment.25, 34, 35

    Sociodemographic and lifestyle characteristics included monthly family per capita income (in US dollars), educational attainment, physical activity level, smoking status, alcohol drinking habits, and use of medications. Current educational attainment was assessed as the highest qualification attained and categorized as undergraduate school or more, complete high school, complete elementary school, and incomplete elementary school. Physical activity included energy expenditure in leisure time by reporting type and duration of activity according to predetermined questionnaire items from the long version of the International Physical Activity Questionnaire.36 The physical activity level was categorized as low, moderate and high. Individuals were categorized according to smoking status as never smoker, former smoker, and current smoker. Never smoking status was defined as lifetime consumption of <100 cigarettes (5 packs of cigarettes). Former smokers were participants with past history of smoking who had not smoked cigarettes within the previous 30 days. Current smoking was defined as consumption of cigarettes within the previous 30 days. Average alcohol consumption was categorized as nondrinker and alcohol drinker. Medicaments use included hypertension, diabetes mellitus, and hypercholesterolemia treatment.

    Physical examination included measurement of height, weight, and blood pressure using standard procedures. Body mass index was calculated by dividing weight (kg) by the square of height (m2), expressed as kg/m2. Blood pressure was measured using a validated oscillometric device (Omron HEM 705CP), handled by a nursing technician. Three measurements were performed at 1‐minute intervals. The mean of the 2 latest blood pressure measurements was used as the high blood pressure definition.34 Hypertension status was defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, use of antihypertensive drug treatment, or both.37

    The blood samples were collected by venipuncture after 12 hours of overnight fasting. All analyses were performed at the University of São Paulo. Serum total cholesterol and fractions, low‐ and high‐density lipoprotein cholesterol, and triglycerides were determined by enzymatic colorimetric assay (ADVIA 1200 Chemistry Analyzer; Siemens). Fasting plasma glucose was measured by hexokinase method (enzymatic; ADVIA 1200 Chemistry Analyzer; Siemens). Diabetes mellitus status was defined as a medical history of diabetes mellitus with a physician diagnosis and/or the reported use of medications to treat diabetes mellitus (insulin or oral antidiabetic medication) and/or fasting plasma glucose >126 mg/dL, glycated hemoglobin ≥6.5%, or 2‐hour plasma glucose after an overload of 75 g glucose in ≥200 mg/dL (5.17 mmol/L).26 Other details on logistics of collection, processing, transportation of biological samples, and organization of the central laboratory in ELSA‐Brasil are available elsewhere.35

    Statistical Analyses

    Baseline characteristics of the sample were summarized using median and interquartile range for continuous variables and frequencies and percentages for categorical variables according to coffee consumption categories (never/almost never, ≤1, 1–3, and >3 cups/d). Differences between coffee consumption categories were performed using the χ2 test for categorical variables and the Kruskall–Wallis test for continuous variables.

    Multiple logistic regression analysis was performed to estimate odds ratios and 95% confidence intervals (95% CIs) for the association between the independent variable (categories of coffee consumption) and category of CAC score (<100 versus ≥100), as the dependent variable. The effect of interaction between smoking status and coffee consumption on subclinical coronary calcification was tested by including the respective multiplicative interaction terms in the logistic regression model. Thereafter, the multivariate model was adjusted for established risk factors for CVD that were also known to be associated with coffee consumption based on prior studies and theoretical considerations, according to the literature, as follows: age (years), sex (male and female), self‐reported race/skin color (white and nonwhite), current educational attainment (complete elementary school, complete high school, and undergraduate school or more), physical activity level (low, moderate, and high), body mass index (kg/m2), smoking status (never, former, and current smokers), alcohol consumption (nondrinker and drinker), saturated fat (g/d), consumption of fruit and vegetables (g/d), tea drinking (mL/d), total energy intake (kcal/d), blood pressure (mm Hg), fasting glucose (mg/dL), high‐density lipoprotein cholesterol (mg/dL), low‐density lipoprotein cholesterol (mg/dL), triglyceride (mg/dL), and use of antihypertensive, antidiabetic, or cholesterol‐lowering medications. Because an interaction was found for smoking status (P=0.028), the analysis was performed after stratification of the sample by this variable.

    All statistical analyses were conducted using the Stata statistical software package, version 13.0 (StataCorp), and P<0.05 was considered statistically significant. The P value for trend of continuous variables using ANOVA was also determined.


    The final study population had a median age of 50.0 years, was mostly female (54.2%), was self‐declared white (58.9%), had a low physical activity level (78.7%), and was overweight or obese (65.4%). Of the participants, 2360 were never smokers (53.3%), 1356 were former smokers (30.7%), and 710 were current smokers (16.0%). The prevalence of CAC ≥100 was 9.9%. Most participants (≈56%) reported consuming coffee at least twice per day, with 515 (11.6% of the total) reporting consuming coffee >3 times per day. Most participants reported typically consuming coffee that was filtered (81.7%) and caffeinated (98.6%) and using added sugar (59.0%) or artificial sweetener (28.2%).

    The baseline characteristics of the studied population according to coffee consumption categories are shown in Table 1. Coffee consumption was related to age, white race or skin color, educational level, physical activity level, smoking status, alcohol intake, tea consumption, fruit and vegetable consumption, saturated fat, and total energy intake.

    Table 1. Baseline Characteristics of ELSA‐Brasil Participants (N=4426) By Categories of Coffee Consumption per Day, São Paulo, 2008–2010

    CharacteristicsCoffee Consumption, Number of 50‐mL Cups/d
    TotalNever/Almost Never≤11–3>3P Valuea,b
    No. of participants44269719591981515
    Age (y), median (IQR)50 (44–57)51 (45–58)50 (44–56)49 (45–55)49 (44–55)<0.001a
    Sex, n (%)
    Male2027 (45.8)447 (46.0)428 (44.6)920 (46.4)232 (45.0)0.802b
    Female2399 (54.2)524 (54.0)531 (55.4)1061 (53.6)283 (55.0)
    Race/skin color, n (%)
    White2574 (58.9)635 (66.9)514 (53.9)1136 (58.2)289 (56.3)<0.001b
    Other1794 (41.1)314 (33.1)439 (46.1)817 (41.8)224 (43.7)
    Educational Attainment, n (%)
    Complete elementary school655 (14.8)86 (8.9)194 (20.2)301 (15.2)74 (14.4)
    Complete high school1819 (41.1)278 (28.6)411 (42.9)872 (44.0)258 (50.1)<0.001b
    Undergraduate school or more1952 (44.1)607 (62.5)354 (36.9)808 (40.8)183 (35.5)
    Physical activity level, n (%)
    Low3358 (78.7)661 (70.7)741 (79.6)1567 (81.6)389 (81.0)
    Moderate554 (13.0)151 (16.2)126 (13.5)212 (11.0)65 (13.6)<0.001b
    High356 (8.3)123 (13.1)64 (6.9)143 (7.4)26 (5.4)
    Smoking status, n (%)
    Never smoker2360 (53.3)584 (60.1)579 (60.4)939 (47.4)258 (50.1)<0.001b
    Former smoker1356 (30.7)296 (30.5)281 (29.3)610 (30.8)169 (32.8)
    Current smoker710 (16.0)91 (9.4)99 (10.3)432 (21.8)88 (17.1)
    Clinical and physical characteristics
    Body mass index (kg/m2), median (IQR)26.8 (24.0–30.0)26.5 (23.7–29.6)26.7 (23.9–29.9)26.7 (24.1–30.0)27.4 (24.1–30.3)0.174a
    Hypertension, n (%)
    No3068 (69.3)695 (71.6)643 (67.0)1380 (69.7)350 (68.0)0.156b
    Yes1357 (30.7)276 (28.4)316 (33.0)600 (30.3)165 (32.0)
    Diabetes mellitus, n (%)
    No3547 (80.1)788 (81.1)750 (78.2)1595 (80.5)414 (80.4)0.380b
    Yes879 (19.9)183 (18.9)209 (21.8)386 (19.5)101 (19.6)
    LDL‐C (mg/dL), median (IQR)128 (108–150)128 (108–150)128 (107–149)127 (107–151)131 (111–152)0.349a
    HDL‐C (mg/dL), median (IQR)54 (46–64)55 (47–67)53 (46–64)53 (46–63)53 (46–63)0.020a
    TG (mg/dL), median (IQR)115 (81–164)113 (79–160)117 (79–170)114 (83–164)121 (83–166)0.325a
    Daily dietary data
    Alcohol user, n (%)3019 (68.2)697 (71.8)605 (63.1)1377 (69.5)340 (66.0)<0.001a
    Tea consumption (mL/d), median (IQR)0 (0–87)21 (0–174)0 (0–87)0 (0–87)0 (0–44)<0.001a
    Fruit and vegetable consumption (g/d), median (IQR)653.9 (437.5–940.1)643.2 (423.7–952.1)663.3 (436.4–917.7)646.2 (440.6–915.2)687.2 (461.7–1031.3)0.019a
    Saturated fat (g/d), median (IQR)23.3 (19.6–27.2)23.6 (20.3–27.5)22.9 (19.8–26.9)23.3 (19.3–27.4)22.7 (18.5–27.1)0.007a
    Total energy intake (kcal/d), median (IQR)2208.6 (1697.3–2888.7)2070.9 (1558.3–2730.8)2147.8 (1652.6–2767.7)2234.1 (1758.4–2903.6)2515.4 (1896.9–3452.9)<0.001a

    Values are median (IQR) for continuous variables and frequencies and percentages for categorical variables. P<0.05 was considered statistically significant. ELSA‐Brasil indicates Brazilian Longitudinal Study of Adult Health; HDL‐C, high‐density lipoprotein cholesterol; IQR, interquartile range; LDL‐C, low‐density lipoprotein cholesterol; TG, triglycerides.

    aComparisons across categories were performed by using Kruskall–Wallis test.

    bComparisons across categories were performed by using χ2.

    The association between coronary calcification and coffee consumption categories, considering the coffee–smoking interaction, is depicted in Table 2. After multivariate adjustment, there was a statistically significant interaction effect for coffee consumption and smoking status on CAC ≥100 (P=0.028 for interaction). Moreover, significant inverse association was observed between coffee consumption (>3 cups/d) and CAC (≥100 Agatston units). The odds ratios for CAC ≥100 in participants who consumed coffee compared with those who never drank coffee were 0.85 (95% CI, 0.58–1.24), 0.73 (95% CI, 0.51–1.05), and 0.33 (95% CI, 0.17–0.65) for ≤1, 1 to 3, and >3 cups/d (P=0.015 for trend). Table 3 presents the results of the stratified analysis according to smoking status. The odds ratio of subclinical coronary atherosclerosis among current and former smokers was not significantly associated with coffee consumption, whereas among never smokers, the intake of coffee up to 3 cups/d was associated with lower odds of coronary calcification (odds ratio: 0.37 [95% CI, 0.15–0.91]; P=0.036 for trend).

    Table 2. ORs and 95% CIs of Subclinical Coronary Calcification (CAC ≥100 vs <100) by Categories of Coffee Consumption Considering Smoking Status and Coffee Intake Interaction (ELSA‐Brasil, São Paulo, 2008–2010)

    CAC Score Category, OR (95% CI)Coffee Consumption, Number of 50‐mL Cups/d
    Never/Almost Never≤11–3>3P for TrendaP for Interactiona,b
    CAC ≥100 vs <100
    No. of cases1139219838
    Total population (without interaction term)
    Model 1 (crude)1.00 (Ref.)0.80 (0.60–1.07)0.84 (0.66–1.08)0.60 (0.41–0.89)0.027
    Model 2 (adjusted)1.00 (Ref.)0.89 (0.61–1.30)0.86 (0.63–1.19)0.51 (0.30–0.86)0.039
    Total population (with interaction term)
    Model 1 (crude)1.00 (Ref.)0.82 (0.61–1.11)0.84 (0.61–1.13)0.70 (0.40–1.23)0.2190.300
    Model 2 (adjusted)1.00 (Ref.)0.85 (0.58–1.24)0.73 (0.51–1.05)0.33 (0.17–0.65)0.0150.028

    Model 2: adjusted for age, sex, race or skin color, educational attainment, body mass index, physical activity level, smoking status, alcohol consumption, saturated fat, total energy intake, consumption of fruit, vegetable and tea intake, systolic and diastolic blood pressure, fasting glucose, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, triglyceride, and use of antihypertensive, antidiabetic, and cholesterol‐lowering medications. CAC indicates coronary artery calcium; CI, confidence interval; ELSA‐Brasil indicates Brazilian Longitudinal Study of Adult Health; OR, odds ratio; Ref., reference.

    aP<0.05 was considered statistically significant.

    bInteraction between coffee consumption and smoking status.

    Table 3. ORs and 95% CIs of Subclinical Coronary Calcification (CAC ≥100 vs <100) in Never, Former, and Current Smokers by Categories of Coffee Consumption (ELSA‐Brasil, São Paulo, 2008–2010)

    CAC Score CategoryCoffee Consumption, Number of 50‐mL Cups/d
    (CAC ≥100 vs <100), OR (95% CI)Never/Almost Never≤11–3>3P for Trenda
    Never smokers
    No. of participants584579939258
    No. of cases54396817
    Model 1 (crude)1.00 (Ref.)0.90 (0.57–1.42)0.71 (0.48–1.05)0.44 (0.23–0.84)0.007
    Model 2 (adjusted)1.00 (Ref.)1.18 (0.63–2.20)0.81 (0.47–1.37)0.37 (0.15–0.91)0.036
    Former smokers
    No. of participants296281610169
    No. of cases47417213
    Model 1 (crude)1.00 (Ref.)0.71 (0.46–1.09)0.77 (0.53–1.11)0.69 (0.39–1.22)0.157
    Model 2 (adjusted)1.00 (Ref.)0.82 (0.46–1.45)0.86 (0.52–1.42)0.55 (0.23–1.31)0.276
    Current smokers
    No. of participants919943288
    No. of cases1212588
    Model 1 (crude)1.00 (Ref.)0.91 (0.38–2.13)1.02 (0.52–1.98)0.66 (0.25–1.70)0.634
    Model 2 (adjusted)1.00 (Ref.)0.75 (0.25–2.29)1.19 (0.50–2.83)0.68 (0.21–2.16)0.976

    Models 2: adjusted for age, sex, race or skin color, educational attainment, body mass index, physical activity level, alcohol consumption, saturated fat, total energy intake, consumption of fruit, vegetable and tea intake, systolic and diastolic blood pressure, fasting glucose, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglyceride, and use of antihypertensive, antidiabetic, and cholesterol‐lowering medications. CAC indicates coronary artery calcium; CI, confidence interval; ELSA‐Brasil indicates Brazilian Longitudinal Study of Adult Health; OR, odds ratio; Ref., reference.

    aP<0.05 was considered statistically significant.


    The current study found that habitual coffee consumption was inversely associated with coronary calcification, a marker of subclinical coronary atherosclerosis, even after adjustments for potential confounders, including cardiovascular risk factors; however, this protective role of coffee on coronary calcification was nullified by smoking habit.

    The benefits of coffee consumption on the cardiovascular system have been investigated extensively, providing inconsistent and conflicting results according to different study designs.5, 6 In the 1980s, cross‐sectional studies found a positive association between coffee consumption and serum total cholesterol concentrations, which might be related to the coffee‐brewing method (ie, boiled or unfiltered coffee). Case–control studies, which are prone to recall and selection biases, tended to show a positive association, whereas cohort studies generally suggested a null association, although results varied substantially across studies and findings have remained inconsistent.12

    More recent meta‐analysis of prospective studies showed that moderate coffee consumption was associated with decreased CVD risk, all‐cause mortality, and mortality attributed to CVD and neurologic disease in the overall population. High coffee consumption (>5 cups/d) was neither related to CVD risk nor to risk of mortality.12, 13 To corroborate this evidence, the 2015–2020 Dietary Guidelines for Americans show that consumption of 3 to 5 cups/d of coffee is associated with reduced risk of type 2 diabetes mellitus and CVD in adults.38 Consequently, moderate coffee consumption can be incorporated into a healthy dietary pattern, along with other healthful behaviors.38

    Although coffee consumption has been studied in relation to various risk factors of CVD, only 4 studies have investigated the association between coffee intake and subclinical atherosclerosis,21, 22, 23, 24 and the data available were limited and inconsistent.

    According to Choi et al,23 in the large sample of Korean men and women apparently free of clinically evident CVD (n=25 138), moderate coffee consumption (3 to <5 cups/d) was associated with 41% lower prevalence of CAC. The results from our study are comparable to this research. In the study by Choi et al, however, the average age of the study participants was 41 years, 84% of the participants were male, and ≈82% completed college graduation or higher, thus the results might not be generalizable to the other populations. In the Rotterdam study (n=1570), van Woudenbergh et al21 showed that moderate (>3 to 4 cups/d) to high (>4 cups/d) coffee consumption was associated with decreased prevalence of severe calcification (CAC score >400) in women, but an increased risk was observed in nonsmoking men. These investigators were unable to explain why coffee appeared to be protective among women but harmful among nonsmoking men. Smoking behavior may wield a strong influence on an association between coffee consumption and CVD risk. Smokers are often more frequent coffee drinkers,39 and they are also inherently at greater risk of coronary artery disease39 and positively associated with subclinical atherosclerosis.40, 41 Smoking may also intercede in the pathways through which coffee constituents are hypothesized to mediate effects on this disease. If caffeine and coffee‐derived antioxidants are important mediators of the association between coffee consumption and subclinical atherosclerosis, it is possible that deleterious effects of smoking overwhelm the influence of coffee intake on early CVD injury. Consequently, this impact of coffee may only be detectable in people who have never smoked. In stratified analysis, we are able to remove residual confounding by smoking status from our data; therefore, our results support the evidence that the beneficial effects of coffee intake on coronary artery calcification were observed only in never smokers.

    Contrary to our findings, 2 other studies22, 24 have shown that there was no association between habitual coffee consumption and coronary atherosclerosis in adults. In the CARDIA (Coronary Artery Risk Development in Young Adults) study (N=5115),22 caffeinated and decaffeinated coffee consumption was not associated with coronary calcification or with progression over 5 years of follow‐up. Participants in the CARDIA study were younger (mean age: 26 years) and consumed less coffee (16% reported consuming ≥3 cups/d). In the NHLBI Family Heart Study (n=1929),24 prevalence ratios for CAC ≥100 were 1.0 (reference), 0.92 (95% CI, 0.57–1.49), 1.34 (95% CI, 0.86–2.08), 1.30 (95% CI, 0.84–2.02), and 0.99 (95% CI, 0.60–1.64) for coffee consumption of almost never, <1, 1, 2 to 3, and ≥4 cups/d, respectively, in adult men and women.

    These controversial findings across studies could also be attributable to different types of studies and methodological issues, including differences in sample size, statistical adjustments for potential confounding factors, measures and different coffee‐brewing methods, daily consumption, distinct characteristics of study populations (age, sex, ethnicity, educational level), and prevalence of CAC.

    Regarding the biological mechanisms, several pathways have been suggested for the potential beneficial relationship between coffee consumption and cardiovascular risk. It might be possible that the protective effect of coffee consumption comes through different physiology that reduces the long‐term effects of traditional risk factors responsible for CVD. Habitual coffee consumption has been associated with a significantly lower risk of type 2 diabetes mellitus,42, 43 a major risk factor for atherosclerosis. In addition, coffee drinking might improve insulin sensitivity, apparently because of the presence of antioxidant compounds in the coffee.44 Despite the fact that acute coffee consumption might increase blood pressure, this effect seems to disappear with long‐term coffee consumption, and large prospective studies do not support the hypothesis that high coffee consumption increases the risk of hypertension.45, 46 Coffee is a beverage with very complex chemical composition, rich in phenolic compounds, predominantly hydroxycinnamic acids, which demonstrate protective roles in the cardiovascular system.4 This cardiovascular protection has been confirmed in vivo and can be explained by various mechanisms, including their anti‐inflammatory properties,47 strong antioxidant activity48, 49 that might prevent low‐density lipoprotein oxidation,49 and antithrombotic capacities associated with improved endothelial function and nitric oxide bioavailability,50, 51 protecting against thrombus formation or atherosclerotic lesion development. Conversely, coffee, particularly unfiltered coffee, has been associated with alterations in circulating lipids, because it is rich in cholesterol‐raising compounds (diterpenes, kahweol, and cafestol) that contribute significantly to the increase in total cholesterol, low‐density lipoprotein cholesterol, and triglycerides.52, 53, 54 Consumption of filtered coffee, however, had no substantial effects on blood lipids,52, 55 because the brewing releases oil droplets containing diterpenes from ground coffee beans, and the oil is retained by a paper filter.52, 54 In Brazil, filtering is the traditional method of coffee preparation, so our study corroborated and supported this information. Besides, the antioxidants included in coffee might reduce lipid oxidation, as mentioned earlier.

    Some limitations of this study should be considered when interpreting results. Although ELSA‐Brasil is a prospective cohort study, at this moment, we only have available data from the baseline examination; therefore, the cross‐sectional design limits the possibility of establishing causal inferences, because we cannot rule out reverse causation or residual confounding. Nevertheless, to minimize the problem of reverse causality, we excluded participants with previously diagnosed CVD from the analyses. Finally, our results were based on a sample of relatively healthy middle‐aged participants with a high educational level, thus they might not be generalizable to other populations. Further research is warranted to confirm our findings and to establish the biological basis of coffee's potential preventive effects on coronary artery disease.

    Our study, however, has several strengths. The large sample size provides sufficient power to detect the association between coffee drinking and CAC scores while controlling for several potential confounders. Data collection in ELSA‐Brasil is subject to carefully standardized protocols and rigorous quality control. In addition, we had information on a large number of CVD risk factors that could be used to adjust for potential confounders in multivariable models. Moreover, we used the CAC measurement to assess coronary atherosclerosis, a method with good reproducibility and correlation with the extent of coronary artery disease.

    In conclusion, the current study showed that the association between coffee consumption and coronary calcification was related to smoking status. Habitual coffee drinking of >3 cups/d was associated with lower odds of subclinical coronary atherosclerosis among never smokers in a Brazilian population. Our findings suggest that coffee consumption could exert a potential beneficial effect against coronary calcification and CVD risk, particularly in nonsmokers.


    We would like to acknowledge the participation of the 15 105 individuals recruited, without whom this study and those based on the ELSA‐Brasil (Brazilian Longitudinal Study of Adult Health) cohort would not have been possible. Author Contributions: Designed the study's analytic strategy: Miranda, Marchioni. Analyzed the data: Miranda, Steluti, Marchioni. Wrote the article: Miranda. Discussion and final review: Miranda, Steluti, Goulart, Benseñor, Lotufo, Marchioni. All authors read and approved the final version of the article.

    Sources of Funding

    The ELSA‐Brasil (Brazilian Longitudinal Study of Adult Health) baseline study was supported by the Brazilian Ministry of Health (Science and Technology Department) and the Brazilian Ministry of Science and Technology and National Research Council (grants 01 06 0010.00 RS, 01 06 0212.00 BA, 01 06 0300.00 ES, 01 06 0278.00 MG, 01 06 0115.00 SP, and 01 06 0071.00 RJ). The research center of São Paulo was also supported by São Paulo Research Foundation (FAPESP; grant 2011/12256‐4). Miranda received a scholarship from the FAPESP (grant 2014/04540‐2). No funding agencies had a role in the study design, data collection, analysis, decision to publish, or preparation of the article.




    *Correspondence to: Dirce Maria Marchioni, PhD, Departamento de Nutrição, Faculdade de Saúde Pública, School of Public Health, University of São Paulo, Av. Dr Arnaldo, 715, Cerqueira César, CEP 01246‐000, São Paulo, SP, Brasil. E‐mail:


    • 1 GBD 2015. Mortality and Causes of Death Collaborators . Global, regional, and national life expectancy, all‐cause and cause‐specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388:1459–1544.Google Scholar
    • 2 Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee; Stroke Statistics Subcommittee . Heart disease and stroke statistics‐2016 update: a report from the American Heart Association. Circulation. 2016; 133:e38–e360.Google Scholar
    • 3 GBD 2013 DALYs and HALE Collaborators , Murray CJ, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, Abd‐Allah F, Abera SF, Aboyans V, Abraham JP, Abubakar I, Abu‐Raddad LJ, Abu‐Rmeileh NM, Achoki T, Ackerman IN, Ademi Z, Adou AK, Adsuar JC, Afshin A, Agardh EE, Alam SS, Alasfoor D, Albittar MI, Alegretti MA, Alemu ZA, Alfonso‐Cristancho R, Alhabib S, Ali R, Alla F, Allebeck P, Almazroa MA, Alsharif U, Alvarez E, Alvis‐Guzman N, Amare AT, Ameh EA, Amini H, Ammar W, Anderson HR, Anderson BO, Antonio CA, Anwari P, Arnlöv J, Arsic Arsenijevic VS, Artaman A, Asghar RJ, Assadi R, Atkins LS, Avila MA, Awuah B, Bachman VF, Badawi A, Bahit MC, Balakrishnan K, Banerjee A, Barker‐Collo SL, Barquera S, Barregard L, Barrero LH, Basu A, Basu S, Basulaiman MO, Beardsley J, Bedi N, Beghi E, Bekele T, Bell ML, Benjet C, Bennett DA, Bensenor IM, Benzian H, Bernabé E, Bertozzi‐Villa A, Beyene TJ, Bhala N, Bhalla A, Bhutta ZA, Bienhoff K, Bikbov B, Biryukov S, Blore JD, Blosser CD, Blyth FM, Bohensky MA, Bolliger IW, Bora Başara B, Bornstein NM, Bose D, Boufous S, Bourne RR, Boyers LN, Brainin M, Brayne CE, Brazinova A, Breitborde NJ, Brenner H, Briggs AD, Brooks PM, Brown JC, Brugha TS, Buchbinder R, Buckle GC, Budke CM, Bulchis A, Bulloch AG, Campos‐Nonato IR, Carabin H, Carapetis JR, Cárdenas R, Carpenter DO, Caso V, Castañeda‐Orjuela CA, Castro RE, Catalá‐López F, Cavalleri F, Çavlin A, Chadha VK, Chang JC, Charlson FJ, Chen H, Chen W, Chiang PP, Chimed‐Ochir O, Chowdhury R, Christensen H, Christophi CA, Cirillo M, Coates MM, Coffeng LE, Coggeshall MS, Colistro V, Colquhoun SM, Cooke GS, Cooper C, Cooper LT, Coppola LM, Cortinovis M, Criqui MH, Crump JA, Cuevas‐Nasu L, Danawi H, Dandona L, Dandona R, Dansereau E, Dargan PI, Davey G, Davis A, Davitoiu DV, Dayama A, De Leo D, Degenhardt L, Del Pozo‐Cruz B, Dellavalle RP, Deribe K, Derrett S, Des Jarlais DC, Dessalegn M, Dharmaratne SD, Dherani MK, Diaz‐Torné C, Dicker D, Ding EL, Dokova K, Dorsey ER, Driscoll TR, Duan L, Duber HC, Ebel BE, Edmond KM, Elshrek YM, Endres M, Ermakov SP, Erskine HE, Eshrati B, Esteghamati A, Estep K, Faraon EJ, Farzadfar F, Fay DF, Feigin VL, Felson DT, Fereshtehnejad SM, Fernandes JG, Ferrari AJ, Fitzmaurice C, Flaxman AD, Fleming TD, Foigt N, Forouzanfar MH, Fowkes FG, Paleo UF, Franklin RC, Fürst T, Gabbe B, Gaffikin L, Gankpé FG, Geleijnse JM, Gessner BD, Gething P, Gibney KB, Giroud M, Giussani G, Gomez Dantes H, Gona P, González‐Medina D, Gosselin RA, Gotay CC, Goto A, Gouda HN, Graetz N, Gugnani HC, Gupta R, Gupta R, Gutiérrez RA, Haagsma J, Hafezi‐Nejad N, Hagan H, Halasa YA, Hamadeh RR, Hamavid H, Hammami M, Hancock J, Hankey GJ, Hansen GM, Hao Y, Harb HL, Haro JM, Havmoeller R, Hay SI, Hay RJ, Heredia‐Pi IB, Heuton KR, Heydarpour P, Higashi H, Hijar M, Hoek HW, Hoffman HJ, Hosgood HD, Hossain M, Hotez PJ, Hoy DG, Hsairi M, Hu G, Huang C, Huang JJ, Husseini A, Huynh C, Iannarone ML, Iburg KM, Innos K, Inoue M, Islami F, Jacobsen KH, Jarvis DL, Jassal SK, Jee SH, Jeemon P, Jensen PN, Jha V, Jiang G, Jiang Y, Jonas JB, Juel K, Kan H, Karch A, Karema CK, Karimkhani C, Karthikeyan G, Kassebaum NJ, Kaul A, Kawakami N, Kazanjan K, Kemp AH, Kengne AP, Keren A, Khader YS, Khalifa SE, Khan EA, Khan G, Khang YH, Kieling C, Kim D, Kim S, Kim Y, Kinfu Y, Kinge JM, Kivipelto M, Knibbs LD, Knudsen AK, Kokubo Y, Kosen S, Krishnaswami S, Kuate Defo B, Kucuk Bicer B, Kuipers EJ, Kulkarni C, Kulkarni VS, Kumar GA, Kyu HH, Lai T, Lalloo R, Lallukka T, Lam H, Lan Q, Lansingh VC, Larsson A, Lawrynowicz AE, Leasher JL, Leigh J, Leung R, Levitz CE, Li B, Li Y, Li Y, Lim SS, Lind M, Lipshultz SE, Liu S, Liu Y, Lloyd BK, Lofgren KT, Logroscino G, Looker KJ, Lortet‐Tieulent J, Lotufo PA, Lozano R, Lucas RM, Lunevicius R, Lyons RA, Ma S, Macintyre MF, Mackay MT, Majdan M, Malekzadeh R, Marcenes W, Margolis DJ, Margono C, Marzan MB, Masci JR, Mashal MT, Matzopoulos R, Mayosi BM, Mazorodze TT, Mcgill NW, Mcgrath JJ, Mckee M, Mclain A, Meaney PA, Medina C, Mehndiratta MM, Mekonnen W, Melaku YA, Meltzer M, Memish ZA, Mensah GA, Meretoja A, Mhimbira FA, Micha R, Miller TR, Mills EJ, Mitchell PB, Mock CN, Mohamed Ibrahim N, Mohammad KA, Mokdad AH, Mola GL, Monasta L, Montañez Hernandez JC, Montico M, Montine TJ, Mooney MD, Moore AR, Moradi‐Lakeh M, Moran AE, Mori R, Moschandreas J, Moturi WN, Moyer ML, Mozaffarian D, Msemburi WT, Mueller UO, Mukaigawara M, Mullany EC, Murdoch ME, Murray J, Murthy KS, Naghavi M, Naheed A, Naidoo KS, Naldi L, Nand D, Nangia V, Narayan KM, Nejjari C, Neupane SP, Newton CR, Ng M, Ngalesoni FN, Nguyen G, Nisar MI, Nolte S, Norheim OF, Norman RE, Norrving B, Nyakarahuka L, Oh IH, Ohkubo T, Ohno SL, Olusanya BO, Opio JN, Ortblad K, Ortiz A, Pain AW, Pandian JD, Panelo CI, Papachristou C, Park EK, Park JH, Patten SB, Patton GC, Paul VK, Pavlin BI, Pearce N, Pereira DM, Perez‐Padilla R, Perez‐Ruiz F, Perico N, Pervaiz A, Pesudovs K, Peterson CB, Petzold M, Phillips MR, Phillips BK, Phillips DE, Piel FB, Plass D, Poenaru D, Polinder S, Pope D, Popova S, Poulton RG, Pourmalek F, Prabhakaran D, Prasad NM, Pullan RL, Qato DM, Quistberg DA, Rafay A, Rahimi K, Rahman SU, Raju M, Rana SM, Razavi H, Reddy KS, Refaat A, Remuzzi G, Resnikoff S, Ribeiro AL, Richardson L, Richardus JH, Roberts DA, Rojas‐Rueda D, Ronfani L, Roth GA, Rothenbacher D, Rothstein DH, Rowley JT, Roy N, Ruhago GM, Saeedi MY, Saha S, Sahraian MA, Sampson UK, Sanabria JR, Sandar L, Santos IS, Satpathy M, Sawhney M, Scarborough P, Schneider IJ, Schöttker B, Schumacher AE, Schwebel DC, Scott JG, Seedat S, Sepanlou SG, Serina PT, Servan‐Mori EE, Shackelford KA, Shaheen A, Shahraz S, Shamah Levy T, Shangguan S, She J, Sheikhbahaei S, Shi P, Shibuya K, Shinohara Y, Shiri R, Shishani K, Shiue I, Shrime MG, Sigfusdottir ID, Silberberg DH, Simard EP, Sindi S, Singh A, Singh JA, Singh L, Skirbekk V, Slepak EL, Sliwa K, Soneji S, Søreide K, Soshnikov S, Sposato LA, Sreeramareddy CT, Stanaway JD, Stathopoulou V, Stein DJ, Stein MB, Steiner C, Steiner TJ, Stevens A, Stewart A, Stovner LJ, Stroumpoulis K, Sunguya BF, Swaminathan S, Swaroop M, Sykes BL, Tabb KM, Takahashi K, Tandon N, Tanne D, Tanner M, Tavakkoli M, Taylor HR, Te Ao BJ, Tediosi F, Temesgen AM, Templin T, Ten Have M, Tenkorang EY, Terkawi AS, Thomson B, Thorne‐Lyman AL, Thrift AG, Thurston GD, Tillmann T, Tonelli M, Topouzis F, Toyoshima H, Traebert J, Tran BX, Trillini M, Truelsen T, Tsilimbaris M, Tuzcu EM, Uchendu US, Ukwaja KN, Undurraga EA, Uzun SB, Van Brakel WH, Van De Vijver S, van Gool CH, Van Os J, Vasankari TJ, Venketasubramanian N, Violante FS, Vlassov VV, Vollset SE, Wagner GR, Wagner J, Waller SG, Wan X, Wang H, Wang J, Wang L, Warouw TS, Weichenthal S, Weiderpass E, Weintraub RG, Wenzhi W, Werdecker A, Westerman R, Whiteford HA, Wilkinson JD, Williams TN, Wolfe CD, Wolock TM, Woolf AD, Wulf S, Wurtz B, Xu G, Yan LL, Yano Y, Ye P, Yentür GK, Yip P, Yonemoto N, Yoon SJ, Younis MZ, Yu C, Zaki ME, Zhao Y, Zheng Y, Zonies D, Zou X, Salomon JA, Lopez AD, Vos T. Global, regional, and national disability‐adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015; 386:2145–2191.Google Scholar
    • 4 Guo X, Tresserra‐Rimbau A, Estruch R, Martínez‐González M, Medina‐Remón A, Castañer O, Corella D, Salvadó JS, Lamuela‐Raventós RM. Effects of polyphenol, measured by a biomarker of total polyphenols in urine, on cardiovascular risk factors after a long‐term follow‐up in the PREDIMED Study. Oxid Med Cell Longev. 2016; 2016:2572606.Google Scholar
    • 5 Wu JN, Ho SC, Zhou C, Ling WH, Chen WQ, Wang CL, Chen YM. Coffee consumption and risk of coronary heart diseases: a meta‐analysis of 21 prospective cohort studies. Int J Cardiol. 2009; 137:216–225.Google Scholar
    • 6 Floegel A, Pischon T, Bergmann MM, Teucher B, Kaaks R, Boeing H. Coffee consumption and risk of chronic disease in the European Prospective Investigation into Cancer and Nutrition (EPIC)‐Germany study. Am J Clin Nutr. 2012; 95:901–908.Google Scholar
    • 7 Butt MS, Sultan MT. Coffee and its consumption: benefits and risks. Crit Rev Food Sci Nutr. 2011; 51:363–373.Google Scholar
    • 8 Liu J, Sui X, Lavie CJ, Hebert JR, Earnest CP, Zhang J, Blair SN. Association of coffee consumption with all‐cause and cardiovascular disease mortality. Mayo Clin Proc. 2013; 88:1066–1074.Google Scholar
    • 9 Grioni S, Agnoli C, Sieri S, Pala V, Ricceri F, Masala G, Saieva C, Panico S, Mattiello A, Chiodini P, Tumino R, Frasca G, Iacoviello L, de Curtis A, Vineis P, Krogh V. Espresso coffee consumption and risk of coronary heart disease in a large Italian Cohort. PLoS One. 2015; 10:e0126550.Google Scholar
    • 10 Lopez‐Gracia E, Van Dam RM, Willett WC, Rimm EB, Manson JE, Stampfer MJ, Rexrode KM, Hu FB. Coffee consumption and coronary heart disease in men and women. Circulation. 2006; 113:2045–2053.Google Scholar
    • 11 Lopez‐Garcia E, Rodriguez‐Artalejo F, Rexrode KM, Logroscino G, Hu FB, van Dam RM. Coffee consumption and risk of stroke in women. Circulation. 2009; 119:1116–1123.Google Scholar
    • 12 Ding M, Bhupathiraju SN, Satija A, van Dam RM, Hu FB. Long‐term coffee consumption and risk of cardiovascular disease: a systematic review and a dose‐response meta‐analysis of prospective cohort studies. Circulation. 2014; 129:643–659.Google Scholar
    • 13 Ding M, Satija A, Bhupathiraju SN, Hu Y, Sun Q, Han J, Lopez‐Garcia E, Willett W, van Dam RM, Hu FB. Association of coffee consumption with total and cause‐specific mortality in three large prospective cohorts. Circulation. 2015; 132:2305–2315.Google Scholar
    • 14 Godos J, Pluchinotta FR, Marventano S, Buscemi S, Li Volti G, Galvano F, Grosso G. Coffee components and cardiovascular risk: beneficial and detrimental effects. Int J Food Sci Nutr. 2014; 65:925–936.Google Scholar
    • 15 Tota‐Maharaj R, Blaha MJ, Blankstein R, Silverman MG, Eng J, Shaw LJ, Blumenthal RS, Budoff MJ, Nasir K. Association of coronary artery calcium and coronary heart disease events in young and elderly participants in the multi‐ethnic study of atherosclerosis: a secondary analysis of a prospective, population‐based cohort. Mayo Clin Proc. 2014; 89:1350–1359.Google Scholar
    • 16 Paixão AR, Ayers CR, Rohatgi A, Das SR, de Lemos JA, Khera A, Lloyd‐Jones D, Berry JD. Cardiovascular lifetime risk predicts incidence of coronary calcification in individuals with low short‐term risk: the Dallas Heart Study. J Am Heart Assoc. 2014; 3:e001280. DOI: 10.1161/JAHA.114.001280.Google Scholar
    • 17 Gepner AD, Young R, Delaney JA, Tattersall MC, Blaha MJ, Post WS, Gottesman RF, Kronmal R, Budoff MJ, Burke GL, Folsom AR, Liu K, Kaufman J, Stein JH. Comparison of coronary artery calcium presence, carotid plaque presence, and carotid intima‐media thickness for cardiovascular disease prediction in the multi‐ethnic study of atherosclerosis. Circ Cardiovasc Imaging. 2015; 8:e002262.Google Scholar
    • 18 Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation. 1995; 92:2157–2167.Google Scholar
    • 19 Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, Guerci AD, Lima JA, Rader DJ, Rubin GD, Shaw LJ, Wiegers SE. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation. 2006; 114:1761–1791.Google Scholar
    • 20 Reilly MP, Wolfe ML, Localio AR, Rader DJ. Coronary artery calcification and cardiovascular risk factors: impact of the analytic approach. Atherosclerosis. 2004; 173:69–78.Google Scholar
    • 21 van Woudenbergh GJ, Vliegenthart R, van Rooij FJ, Hofman A, Oudkerk M, Witteman JC, Geleijnse JM. Coffee consumption and coronary calcification: the Rotterdam Coronary Calcification Study. Arterioscler Thromb Vasc Biol. 2008; 28:1018–1023.Google Scholar
    • 22 Reis JP, Loria CM, Steffen LM, Zhou X, van Horn L, Siscovick DS, Jacobs DR, Carr JJ. Coffee, decaffeinated coffee, caffeine, and tea consumption in young adulthood and atherosclerosis later in life: the CARDIA study. Arterioscler Thromb Vasc Biol. 2010; 30:2059–2066.Google Scholar
    • 23 Choi Y, Chang Y, Ryu S, Cho J, Rampal S, Zhang Y, Ahn J, Lima JA, Shin H, Guallar E. Coffee consumption and coronary artery calcium in young and middle‐aged asymptomatic adults. Heart. 2015; 101:686–691.Google Scholar
    • 24 Patel YR, Gadiraju TV, Ellison RC, Hunt SC, Carr JJ, Heiss G, Arnett DK, Pankow JS, Gaziano JM, Djoussé L. Coffee consumption and calcified atherosclerotic plaques in the coronary arteries: The NHLBI Family Heart Study. Clin Nutr ESPEN. 2017; 17:18–21.Google Scholar
    • 25 Aquino EM, Barreto SM, Bensenor IM, Carvalho MS, Chor D, Duncan BB, Lotufo PA, Mill JG, del Molina MC, Mota EL, Passos VM, Schmidt MI, Szklo M. Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil): objectives and Design. Am J Epidemiol. 2012; 175:315–324.Google Scholar
    • 26 Schmidt MI, Duncan BB, Mill JG, Lotufo PA, Chor D, Barreto SM, Aquino EM, Passos VM, Matos SM, del Molina MC, Carvalho MS, Bensenor IM. Cohort profile: longitudinal study of adult health (ELSA‐Brasil). Int J Epidemiol. 2015; 44:68–75.Google Scholar
    • 27 del Molina MC, Bensenor IM, de Cardoso LO, Velasquez‐Melendez G, Drehmer M, Pereira SS, Faria CPF, Melere C, Manato L, Gomes ALC, de Fonseca MJ, Sichieri R. Reproducibility and relative validity of the Food Frequency Questionnaire used in the ELSA‐Brasil. Cad Saude Publica. 2013; 29:379–389.Google Scholar
    • 28 Pereira AC, Gomez LM, Bittencourt MS, Staniak HL, Sharovsky R, Foppa M, Blaha MJ, Bensenor IM, Lotufo PA. Age, gender, and race‐based coronary artery calcium score percentiles in the Brazilian longitudinal study of adult health (ELSA‐Brasil). Clin Cardiol. 2016; 39:352–359.Google Scholar
    • 29 Bensenor IM, Goulart AC, Santos IS, Bittencourt MS, Pereira AC, Santos RD, Nasir K, Blankstein R, Lotufo PA. Association between a healthy cardiovascular risk factor profile and coronary artery calcium score: results from the Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil). Am Heart J. 2016; 174:51–59.Google Scholar
    • 30 Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15:827–832.Google Scholar
    • 31 Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, Flores FR, Callister TQ, Raggi P, Berman DS. Long‐term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007; 49:1860–1870.Google Scholar
    • 32 Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008; 358:1336–1345.Google Scholar
    • 33 de Peixoto Miranda ÉJF, Sommer Bittencourt M, Staniak HL, Pereira AC, Foppa M, Santos IS, Lotufo PA, Bensenor IM. Thyrotropin levels and coronary artery calcification: cross‐sectional results of the Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil). Clin Endocrinol (Oxf). 2017; 87:597–604.Google Scholar
    • 34 Bensenor IM, Griep RH, Pinto KA, Faria CP, Felisbino‐Mendes M, Caetano EI, Albuquerque LS, Schmidt MI. Routines of organization of clinical tests and interviews in the ELSA‐Brasil investigation center. Rev Saud Publica. 2013; 47:37–47.Google Scholar
    • 35 Fedeli LG, Vidigal PG, Leite CM, Castilhos CD, Pimentel RA, Maniero VC, Mill JG, Lotufo PA, Pereira AC, Bensenor IM. Logistics of collection and transportation of biological samples and the organization of the central laboratory in the ELSA‐Brasil. Rev Saude Publica. 2013; 47(suppl 2):63–71.Google Scholar
    • 36 The IPAQ group . International physical activity questionnaire. 2014.Available at: Accessed March 13, 2017.Google Scholar
    • 37 Chor D, Pinho Ribeiro AL, Sá Carvalho M, Duncan BB, Andrade Lotufo P, Araújo Nobre A, Aquino EM, Schmidt MI, Griep RH, Molina Mdel C, Barreto SM, Passos VM, Benseñor IJ, Matos SM, Mill JG. Prevalence, awareness, treatment and influence of socioeconomic variables on control of high blood pressure: results of the ELSA‐Brasil study. PLoS One. 2015; 10:e0127382.Google Scholar
    • 38 U.S. Department of Health and Human Services and U.S. Department of Agriculture . 2015‐2020 Dietary Guidelines for Americans. 8th ed. 2015. Available at: Accessed January 30, 2017.Google Scholar
    • 39 Klatsky AL, Koplik S, Kipp H, Friedman GD. The confounded relation of coffee drinking to coronary artery disease. Am J Cardiol. 2008; 101:825–827.Google Scholar
    • 40 Hisamatsu T, Miura K, Arima H, Kadota A, Kadowaki S, Torii S, Suzuki S, Miyagawa N, Sato A, Yamazoe M, Fujiyoshi A, Ohkubo T, Yamamoto T, Murata K, Abbott RD, Sekikawa A, Horie M, Ueshima H; the Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA) Research Group . Smoking, smoking cessation, and measures of subclinical atherosclerosis in multiple vascular beds in Japanese men. J Am Heart Assoc. 2016; 5:e003738. DOI: 10.1161/JAHA.116.003738.Google Scholar
    • 41 Kianoush S, Yakoob MY, Al‐Rifai M, DeFilippis AP, Bittencourt MS, Duncan BB, Bensenor IM, Bhatnagar A, Lotufo PA, Blaha MJ. Associations of cigarette smoking with subclinical inflammation and atherosclerosis: ELSA‐Brasil (The Brazilian Longitudinal Study of Adult Health). J Am Heart Assoc. 2017; 6:e005088. DOI: 10.1161/JAHA.116.003738.Google Scholar
    • 42 Yarmolinsky J, Mueller NT, Duncan BB, Bisi Molina Mdel C, Goulart AC, Schmidt MI. Coffee consumption, newly diagnosed diabetes, and other alterations in glucose homeostasis: a cross‐sectional analysis of the longitudinal study of adult health (ELSA‐Brasil). PLoS One. 2015; 10:e0126469.Google Scholar
    • 43 Ding M, Bhupathiraju SN, Chen M, van Dam RM, Hu FB. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose‐response meta‐analysis. Diabetes Care. 2014; 37:569–586.Google Scholar
    • 44 Arnlov J, Vessby B, Riserus U. Coffee consumption and insulin sensitivity. JAMA. 2004; 291:1199–1201.Google Scholar
    • 45 Riksen NP, Rongen GA, Smits P. Acute and long‐term cardiovascular effects of coffee: Implications for coronary heart disease. Pharmacol Ther. 2009; 121:185–191.Google Scholar
    • 46 Mesas AE, Leon‐Muñoz LM, Rodriguez‐Artalejo F, Lopez‐Garcia E. The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta‐analysis. Am J Clin Nutr. 2011; 94:1113–1126.Google Scholar
    • 47 Kempf K, Herder C, Erlund I, Kolb H, Martin S, Carstensen M, Koenig W, Sundvall J, Bidel S, Kuha S, Tuomilehto J. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr. 2010; 91:950–957.Google Scholar
    • 48 Richelle M, Tavazzi I, Offord E. Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving. J Agric Food Chem. 2001; 49:3438e42.Google Scholar
    • 49 Natella F, Nardini M, Belelli F, Scaccini C. Coffee drinking induces incorporation of phenolic acids into LDL and increases the resistance of LDL to ex vivo oxidation in humans. Am J Clin Nutr. 2007; 86:604–609.Google Scholar
    • 50 Fuentes E, Palomo I. Mechanisms of endothelial cell protection by hydroxycinnamic acids. Vascul Pharmacol. 2014; 63:155–161.Google Scholar
    • 51 Lopez‐Garcia E, van Dam RM, Qi L, Hu FB. Coffee consumption and markers of inflammation and endothelial dysfunction in healthy and diabetic women. Am J Clin Nutr. 2006; 84:888–893.Google Scholar
    • 52 Ranheim T, Halvorsen B. Coffee consumption and human health‐beneficial or detrimental? Mechanisms for effects of coffee consumption on different risk factors for cardiovascular disease and type 2 diabetes mellitus. Mol Nutr Food Res. 2005; 49:274–284.Google Scholar
    • 53 Cai L, Ma D, Zhang Y, Liu Z, Wang P. The effect of coffee consumption on serum lipids: a meta‐analysis of randomized controlled trials. Eur J Clin Nutr. 2012; 66:872–877.Google Scholar
    • 54 Cano‐Marquina A, Tarín JJ, Cano A. The impact of coffee on health. Maturitas. 2013; 75:7–21.Google Scholar
    • 55 Rebello SA, van Dam RM. Coffee consumption and cardiovascular health: getting to the heart of the matter. Curr Cardiol Rep. 2013; 15:403.Google Scholar


    eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

    Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.